2hr Screener: Biofourmis HQ Location: Boston, Massachusetts

Year Founded	2015
Latest Valuation (post money)	\$1.32B
Total Raised	\$465.00M

patient management and chronic disease care.

condition management.

responses to therapies.

Series B (2019): \$35M

Series C (2020): \$100M Series D (2022): \$320M

Angel (2016): \$1M Series A (2017): \$5M

interventions.

Notable Investors

Product Overview

Core Technology

Previous Funding

Notes

SoftBank Investments, Intel Capital, Peak XV Partners, 2050 Capital, CVS Health Ventures, General Atlantic

health systems. This ecosystem enables seamless communication and data sharing.

comprehensive list of in-home medical services, diagnostics, and support.

Biofourmis offers a technology-enabled care delivery platform that empowers healthcare organizations to deliver personalized, scalable care. The platform is designed to support patients throughout their healthcare journey, from acute care to chronic

The Biofourmis platform integrates real-time health monitoring, Al-driven analytics, and streamlined communication between patients and providers. It enables effective remote patient management, ensuring continuity of care and proactive health

Key competitors include: Livongo, Omada Health, Current Health, Athelas, and Teladoc Health, which are also focused on remote

Biofourmis operates a connected ecosystem that integrates various healthcare stakeholders, including patients, providers, and

Biofourmis collaborates with clinics, labs, pharmacies, nurses, physicians, medical laboratories, and medical devices, providing a

The AI engine develops digital biomarkers based on patient data, which can help in personalizing treatment plans and monitoring

Wearable devices monitor vital signs such as heart rate, respiratory rate, sending data directly to the user's dashboard.

The platform employs advanced machine learning algorithms to analyze health data and generate actionable insights.

The Biofourmis platform is built on a cloud-based infrastructure, which facilitates scalability and flexibility in care delivery.

US digital health market is expected to grow to approximately \$70,010.00M by 2029, from \$47,120.00M in 2024.

Date: 10/08/2024

Intro

- Biofourmis is a leading health technology company focused on transforming healthcare delivery through innovative, technology-enabled solutions. It specializes in remote patient monitoring and AI-driven analytics, partnering with healthcare providers to enhance in-home care and address challenges like hospital capacity and chronic disease management. Committed to improving health outcomes, Biofourmis ensures patients receive timely, personalized care, regardless of location.
 - Berkeley Link: Couldn't find

Initial Highlight/ Traction

- Al driven analytics: Utilizes advanced Al algorithms to generate personalized insights and digital biomarkers, which enhance patient monitoring and care customization.
 Wearable devices: Integrates various wearable devices with its system, enabling real-time data collection, actionable insights, and
- improved patient engagement. Enhances patient monitoring and care delivery.
 In-home medical care: Provides a comprehensive suite of in-home medical services, including remote monitoring, diagnostics, and care coordination, creating a holistic care experience.
- Partnerships: Has with a broad network of healthcare providers, ensuring a coordinated approach to care and leveraging shared expertise.
- Market Growth: US digital health market is expected to grow to approximately \$70,010.00M by 2029, from \$47,120.00M in 2024.

Internal Risks

- High dependence on third-party hardware for patient monitoring.
- Navigating complex healthcare regulations and ensuring compliance with privacy laws (e.g. HIPAA) can be challenging.
- Unclear pricing model, financial metrics, MAU, and customer satisfaction rating.

External Risks

- Growing global demand for digital healthcare and in-home medical services.
- Digital health space is highly competitive, with numerous players emerging, which could impact Biofourmis' market share.
- High reliance on third-party partners for services and integrations introduces risks related to their performance, stability, and alignment with Biofourmis' goals.

Follow Up

Questions

Initial Risks/

Considerat

ions

- What is Biofourmis annual revenue?
- How many monthly active users does Biofourmis have?
- How does Biofourmis plan to differentiate itself further from competitors in the digital health space?
- What are the company's long-term goals in terms of product development and market expansion? Global expansion?
- How does Biofourmis plan to decrease its dependence on multiple partners? Create wearable devices? Hire medical team?

Decision: Continue (P2)